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Background
Characterization of the immunoglobulin gene repertoire has improved our understanding of the
immunopathogenesis of lymphoid tumors. Early B-lymphocyte precursors of multiple myelo-
ma are known to exist and might be susceptible to antigenic drive. 
Design and Methods
To verify this hypothesis, we collected a database of 345 fully readable multiple myeloma
immunoglobulin sequences. We characterized the immunoglobulin repertoire, analyzed the
somatic hypermutation load, and investigated for stereotyped receptor clusters.
Results
Compared to the normal immunoglobulin repertoire, multiple myeloma displayed only modest
differences involving only a few genes, showing that the myeloma immunoglobulin repertoire
is the least skewed among mature B-cell tumors. Median somatic hypermutation load was
7.8%; median length of complementarity determining-region 3 was 15.5 amino acids.
Clustering analysis showed the absence of myeloma specific clusters and no similarity with
published chronic lymphocytic leukemia or lymphoma subsets. 
Conclusions
Analysis of multiple myeloma immunoglobulin repertoire does not support a pathogenetic role
for antigen selection in this tumor.
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ABSTRACT
Introduction
Characterization of the immunoglobulin receptor has
provided useful insights into the pathogenesis and natural
history of lymphoid neoplasms.1-7 In particular, large data-
bases of immunoglobulin heavy chain gene (IGH)
sequences have been analyzed to demonstrate the role of
antigen stimulation as a key environmental driver of
malignant transformation. The recognition of stereotyped
clusters of immunoglobulin receptors in chronic lympho-
cytic leukemia (CLL) provides strong evidence to support
the role of antigen-driven mechanisms in the pathogenesis
of this neoplasm.8-12 Furthermore, recent reports in mantle
cell lymphoma (MCL)13 and marginal zone lymphoma
(MZL)14 have led to speculation that stereotyped clusters
of immunoglobulin receptors might represent a common
phenomenon across most, if not all, mature B-cell tumors.
Although terminally-differentiated malignant plasma
cells (PC) do not express immunoglobulin receptors, it is
known that myelomagenesis is a complex multi-step
process that might involve earlier B-cell precursors.15 In
particular, the class switch recombination mechanisms
involved in multiple myeloma (MM) related chromosomal
translocations suggest that early events in the develop-
ment of MM occur during germinal center (GC) matura-
tion.16 Furthermore, the presence of pre-switch B cells idio-
typically related to malignant PC has been reported.17
Therefore, there is a clear rationale to evaluate the MM
IGH repertoire and to search for stereotyped clusters of
immunoglobulin receptors on appropriately sized patient
series. This will allow us to investigate further into the
role of antigen-driven stimulation in B-lymphoid tumori-
genesis and whether antigen stimulation might play a role
in early myelomagenesis. Published databases of IGH MM
sequences1,6,7 each include less than 80 evaluable patients
and are, therefore, too small to perform extensive cluster
analysis of immunoglobulin receptors. We have combined
a large number of MM IGH sequences obtained at our
institutions for minimal residual disease (MRD) evalua-
tion18 with all the sequences reported in the literature,
leading to a panel of 345 fully evaluable MM IGH
sequences. This database was then used to comprehen-
sively investigate the characteristics of the IGH rearrange-
ment in MM.
Design and Methods
Collection of immunoglobulin sequences 
The original database collected for this study consisted of 406
MM IGH sequences. A total of 237 MM IGH sequences were
retrieved from EMBL, NCBI and IMGT/LIGM-DB public databas-
es, as already reported (Literature Series, LS),10,11,14 while 169 were
directly sequenced at our institutions for MRD purposes
(Institutional Series, IS). All patients provided informed consent in
accordance with the requirements of the local Institutional Review
Board (IRB) and with the Declaration of Helsinki. The study was
approved by the IRB Commissione Regionale per le
Sperimentazioni Cliniche, Turin, Italy. Methods for IGH sequenc-
ing have been described elsewhere.19 Redundant, poorly annotat-
ed, out-of-frame, or clonally related sequences were excluded
from the analysis, as previously reported.10,11,14 Therefore, the final
collection included 345 evaluable IGH MM sequences (MM total,
each sequence corresponding to one single patient), 214 from LS
(Online Supplementary Table S1) and 131 from IS (Online
Supplementary Table S2). For clustering analysis, a total of 28,376
non-MM IGH sequences were retrieved from public databases
(n=26,618)10,11,14 and from our multi-laboratory database
(n=1,758). The non-MM cohort intentionally included several dif-
ferent entities to allow comparison with various types of B cells
(Online Supplementary Table S3). In particular, a subanalysis was
also performed on 461 sequences from PC from healthy donors.
Sequence analysis and data mining
All sequences were aligned to the IMGT directory for the iden-
tification of IGH rearrangements, following established crite-
ria.10,11,20 IGHV, IGHD, and IGHJ gene usage, somatic hypermuta-
tion (SHM) load, and the complementarity determining region 3
on heavy chain gene (HCDR3) length were recorded for each
sequence. Comparisons in terms of IGHV usage were made
between the MM series and the largest published series of IGHV
sequences from healthy donors.10 Only smaller comparative series
from healthy donors were available to compare IGHD-J usage,
mutational load, and HCDR3 length distribution.10, 21-26 
HCDR3-driven clustering
Clustering analysis was performed using ClustalX 2.0, as previ-
ously described.10,27 Stereotyped HCDR3 sequences were those
characterized by an aminoacidic identity of 60% or over, accord-
ing to the criteria of Messmer and Stamatopoulos.10,28 Subsets not
previously described and including only two sequences (‘provi-
sional’) were only considered if they fulfilled the following addi-
tional criteria:11,12,14 i) use of IGHV germline genes of the same clan;
ii) use of the same IGHD and IGHJ germline genes; iii) use of the
same IGHD segment reading frame; and iv) identical HCDR3
length. 
Statistical analysis
Patients’ characteristics were tested using Fisher’s exact test for
discrete variables and the Mann-Whitney test for continuous vari-
ables. All reported P values were obtained by a two-sided exact
method, at the conventional 5% significance level. Data were ana-
lyzed as of April 2011 using SPSS 19.0.0 software.
Results and Discussion
We analyzed the largest database of IGH sequences
from MM patients, consisting of 345 fully evaluable MM
sequences partly derived from our institutional database
(38%) and partly retrieved from published databases
(62%). Usage of IGHV-D-J genes is shown in Figure 1 and
Online Supplementary Figures S1 and S2, and described in
detail in the Online Supplementary Table S4.
Overall, the most frequently reported IGHV families in
MM were IGHV3 (53.9%), IGHV4 (18.6%) and IGHV1
(12.5%). The most frequently reported IGHV genes were
IGHV3-30-3 (9.3%), IGHV3-23 (8.7%) and IGHV1-69
(5.8%), together representing 23.8% of the entire IGHV
repertoire; this is much less than that observed in CLL
(30%), MCL (40%) and MZL (45%) (Figure 2).10,13,14 The
most frequently reported IGHD genes were IGHD3-10
(11.3%), IGHD3-22 (8.1%) and IGHD3-3 (8.1%), while
the IGHJ4 gene by itself accounted for more than half of
the patients’ IGHJ repertoire (54.8%), in line with post-
GC B-cell IGHJ usage.30
The IS IGHV-D-J repertoire was essentially in line with
LS and previously published smaller MM repertoires.1,6,7
The few modest differences (Online Supplementary Tables
S4 and S5) might be due to technical or interpretative bias-
s. Ferrero et al.
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es in the context of the highly hypermutated repertoire of
MM, particularly when dealing with older studies. In con-
trast, the complete absence of IGHV3-21 in a North-
American MM series1 might be the result of technical dif-
ferences in IGH sequencing methods or the expression of
some yet unexplained geographical variation, already
reported for this gene in CLL.31
Despite a global picture representing a nearly physiolog-
ical IGH repertoire in MM, we were able to demonstrate
the presence of modest over and underrepresentation of
some genes compared to normal IGHV repertoire.10 In par-
ticular, we observed overrepresentation of IGHV1-69,
IGHV2-5, IGHV2-70, IGHV3-21, IGHV3-30-3, IGHV3-
43, IGHV5-51 and IGHV6-1 genes, and underrepresenta-
tion of IGHV1-18, IGHV1-8, IGHV3-30, IGHV3-53 and
IGHV4-34 genes (Online Supplementary Figure S3). When
the comparison was restricted only to a panel of 461 PC
sequences derived from healthy donors,10 the skewing of
the MM IGHV repertoire was even less pronounced,
resulting only in an overrepresentation of IGHV2-70,
IGHV3-21 and IGHV3-30-3 genes and in an underrepre-
sentation of IGHV1-2, IGHV1-8, IGHV3-30 and IGHV4-
34 (Online Supplementary Figure S4). On the other hand,
there were no significant differences in IGHD and IGHJ
usage in MM when compared to the normal IGHD-IGHJ
repertoire from both unselected B cells from healthy
donors10, 21-26 and from selected healthy PC,10 with the
exception of the underrepresentation of IGHJ6 (14.5% vs.
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Figure 1. IGHV gene
usage of multiple myelo-
ma total series. MM:
multiple myeloma; IGHV:
immunoglobulin heavy
chain variable region.
Figure 2. IGHV gene usage
in multiple myeloma,
other B-cell malignancies
and  healthy plasma cells.
In black the contribution
of the three most frequent
genes in MM, other B-cell
malignancies and healthy
plasma cells to the totality
of their IGHV repertoire.
IGHV: immunoglobulin-
heavy chain variable
region; MM: multiple
myeloma; PC: plasma
cells; CLL: chronic lympho-
cytic leukemia; MCL: man-
tle cell lymphoma; MZL:
marginal zone lymphoma.
For PC, MCL and MZL
databases, see 10,13,14 while
CLL database has been
retrieved from: Darzentas
N, et al.29
10.0%
8.0%
6.0%
4.0%
2.0%
0.0%
1-
18 1-
2
1-
24 1-
3
1-
46
1-
69
2-
26 2-
5
2-
70
3-
11
3-
13
3-
15
3-
20
3-
21
3-
23
3-
30
3-
30
-3
3-
33
3-
43
3-
48
3-
49
3-
64
3-
66 3-
7
3-
73
3-
74 3-
9
4-
28
4-
30
-2
4-
30
-4
4-
31
4-
34
4-
39 4-
4
4-
59
4-
61 4-
b
5-
51 5-
4
6-
1
IGHV gene usage
IGHV gene usage
MM total series
(n=345)
Healthy PC (n=461)
CLL (n=2,662)
MZL (n=133)
MCL (n=807)
24.6% in healthy B-cell published repertoires; P<0.001;
data not shown) which agrees with IGHJ gene distribution
in post-GC B cells.30 These modest skewings observed in
MM might potentially reflect the expression of processes
different to antigen selection. Finally, our study confirmed
previous observations of a lower incidence of IGHV4-34
in MM compared to healthy B cells and PC IGHV reper-
toire, in accordance with the paucity of autoimmune phe-
nomena in myeloma.1,6,7
Our series also confirms the high rate of SHM in MM
and this agrees with previous studies,1,6,7 supporting the
hypothesis that the transforming events leading to full-
blown myeloma occur in a post-GC memory B cell. There
were 4 out of 345 (1.2%) MM sequences with a germline
identity of 98% or over and only one patient showed IGH
genes in full germline configuration (100% identity).
Available biological and clinical data for these patients are
described in the Online Supplementary Table S6. In terms of
SHM rate, most MM patients showed a homogeneous
and normal distribution with a median value of 7.8%
(range 0-24.6%, SD 3.7%). This is similar to that observed
in healthy PC series in which, nevertheless, the frequency
of unmutated sequences is higher, possibly due to the
presence of a small proportion of IgM secreting PC (Figure
3A). These features are, therefore, radically different from
those of CLL and other B-cell tumors for which we
observe a more heterogeneous distribution pattern reflect-
ing major pathogenetic and clinical differences.3,4,13,14
Lengths of HCDR3 AA sequences in MM were normally
distributed with a mean value of 15.5 AA (range 6-29, SD
3.89), in accordance with published series of healthy PC
(Figure 3B).
An extensive analysis of the HCDR3 region failed to
find any evidence of stereotyped receptor clusters in MM.
Our sample size for this analysis was more than adequate
since original reports documenting the presence of
HCDR3 clustering in CLL, MCL and MZL included 346,
807, and 133 patients, respectively.9,13,14 As shown in the
Online Supplementary Table S7, even among the best
observed matches, critical features hampered an effective
intra-MM clustering, such as different IGHV-D-J usage
and different HCDR3 lengths. Furthermore, no clusters
were found irrespective of IGHV-D-J usage, even consid-
ering only HCDR3 similarities.10
When MM sequences were compared to a large panel of
28,376 non-MM IGH sequences, only a minority of MM
sequences (n=4, 1.2%) clustered with sequences from
other lymphoid tumors or non-neoplastic B cells. In partic-
ular, no MM sequences clustered with previously
described CLL or non-Hodgkin’s lymphoma (NHL) sub-
sets.10,11,13,14 Only one ‘mixed’ MM-NHL and three MM-
normal or reactive B-cell provisional clusters were
observed, each including only two sequences (Online
Supplementary Table S8). These four non-MM partner
sequences belong to distinctly different conditions which
are difficult to reconcile into a common pathogenetic
mechanism. These might, therefore, represent a kind of
‘background signal’ in the context of a highly diversified
IGH repertoire. Nevertheless, 341 of 345 (98.8%) MM
sequences did not belong to any cluster and could be
defined as heterologous. 
In conclusion, our results clearly indicate that MM has
the least skewed IGH repertoire among mature B-cell
tumors. This shows, along with the absence of clusters of
stereotyped IGH receptors, that the MM IGH repertoire
does not contain prominent markers of specific antigen
selection, in contrast to what is observed in other lympho-
proliferative diseases. However, these conclusions need to
be reconciled with previously reported evidence demon-
strating the existence of MM-related B-cell clones that,
according to their differentiation phase, should retain full
antigen responsivity.17 One may speculate that pre-MM B-
cell clones might respond to an extremely diversified anti-
genic challenge, leading to a very modest skewing of the
normal repertoire. Alternatively, early events in MM
pathogenesis might provide adequate proliferative and
survival advantage to pre-malignant MM-related clones
allowing them to bypass the need for antigenic stimuli.
Finally, pre-malignant MM-related clones might frequent-
ly and stochastically arise during physiological immune
responses, while secondary events leading to full-blown
MM are driven by non-immune mechanisms occurring in
later disease phases. IGH repertoire studies such as ours
are clearly not able to formally exclude a role of antigen
selection during the complex pathway leading to overt
MM. Nevertheless, analysis of the largest MM IGH reper-
toire does not provide any evidence to support the view
that the concept of antigen-driven tumorigenesis could be
transferred beyond the field of CLL and NHL. Nor is there
any evidence in favor of a critical role for antigen-respon-
sive B-cell precursors in the pathogenesis of MM.
s. Ferrero et al.
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Figure 3. Somatic hypermutation load (A) and HCDR3 length distri-
butions (B) of multiple myeloma total series compared to published
series of healthy plasma cells. HCDR3: heavy chain complementar-
ity determining region 3; AA: amino acidic; MM: multiple myeloma
(black line); PC: plasma cells (gray line).10
A
B
100 98 96 94 92 90 88 86 84 82 80 78 76
% identity
5 7 9 11 13 15 17 19 21 23 25 27 29
HCDR3 length (AA)
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
16%
14%
12%
10%
8%
6%
4%
2%
0%
MM total series (n=345)
Healthy PC (n=461)
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
Immunoglobulin gene analysis in multiple myeloma 
haematologica | 2012; 97(6) 853
References
1. Rettig MB, Vescio RA, Cao J, Wu CH, Lee
JC, Han E, et al. VH gene usage is multiple
myeloma: complete absence of the VH4.21
(VH4-34) gene. Blood. 1996;87(7):2846-52.
2. Ottensmeier CH, Thompsett AR, Zhu D,
Wilkins BS, Sweetenham JW, Stevenson
FK. Analysis of VH genes in follicular and
diffuse lymphoma shows ongoing somatic
mutation and multiple isotype transcripts
in early disease with changes during dis-
ease progression. Blood. 1998;91(11):4292-
9. 
3. Damle RN, Wasil T, Fais F, Ghiotto F,
Valetto A, Allen SL, et al. Ig V gene muta-
tion status and CD38 expression as novel
prognostic indicators in chronic lympho-
cytic leukemia. Blood. 1999;94:1840-7. 
4. Hamblin TJ, Davis Z, Gardiner A, Oscier
DG, Stevenson FK. Unmutated Ig V(H)
genes are associated with a more aggressive
form of chronic lymphocytic leukemia.
Blood. 1999;94(6):1848-54. 
5. Kienle D, Kröber A, Katzenberger T, Ott G,
Leupolt E, Barth TF, et al. VH mutation sta-
tus and VDJ rearrangement structure in
mantle cell lymphoma: correlation with
genomic aberrations, clinical characteris-
tics, and outcome. Blood. 2003;102(8):
3003-9.
6. González D, González M, Balanzategui A,
Sarasquete ME, López-Pérez R, Chillón
MC, et al. Molecular characteristics and
gene segment usage in IGH gene rearrange-
ments in multiple myeloma.
Haematologica. 2005;90(7):906-13. 
7. Hadzidimitriou A, Stamatopoulos K,
Belessi C, Lalayianni C, Stavroyianni N,
Smilevska T, et al. Immunoglobulin genes
in multiple myeloma: expressed and non-
expressed repertoires, heavy and light
chain pairings and somatic mutation pat-
terns in a series of 101 cases.
Haematologica. 2006;91(6):781-7. 
8. Fais F, Ghiotto F, Hashimoto S, Sellars B,
Valetto A, Allen SL, et al. Chronic lympho-
cytic leukemia B cells express restricted sets
of mutated and unmutated antigen recep-
tors. J Clin Invest. 1998;102(8):1515-25. 
9. Tobin G, Thunberg U, Karlsson K, Murray
F, Laurell A, Willander K, et al. Subsets with
restricted immunoglobulin gene rearrange-
ment features indicate a role for antigen
selection in the development of chronic
lymphocytic leukemia. Blood. 2004;104(9):
2879-85. 
10. Stamatopoulos K, Belessi C, Moreno C,
Boudjograh M, Guida G, Smilevska T, et al.
Over 20% of patients with chronic lym-
phocytic leukemia carry stereotyped recep-
tors: Pathogenetic implications and clinical
correlations.  Blood. 2007;109(1):259-70. 
11. Bomben R, Dal Bo M, Capello D, Forconi F,
Maffei R, Laurenti L, et al. Molecular and
clinical features of chronic lymphocytic
leukaemia with stereotyped B cell recep-
tors: results from an Italian multicentre
study. Br J Haematol. 2009;144(4):492-506. 
12. Forconi F, Potter KN, Wheatley I, Darzentas
N, Sozzi E, Stamatopoulos K, et al. The nor-
mal IGHV1-69-derived B-cell repertoire
contains stereotypic patterns characteristic
of unmutated CLL. Blood. 2010;115(1):71-
7. 
13. Hadzidimitriou A, Agathangelidis A,
Darzentas N, Murray F, Delfau-Larue MH,
Bredo Pedersen L, et al. Is there a role for
antigen selection in mantle cell lymphoma?
Immunogenetic support from a series of
807 cases. Blood. 2011;118(11):3088-95.
14. Zibellini S, Capello D, Forconi F, Marcatili P,
Rossi D, Rattotti S, et al. Stereotyped pat-
terns of B-cell receptor in splenic marginal
zone lymphoma. Haematologica. 2010;95
(10):1792-6.
15. Hideshima T, Bergsagel PL, Kuehl WM,
Anderson KC. Advances in biology of mul-
tiple myeloma: clinical applications. Blood.
2004;104(3):607-18.
16. González D, van der Burg M, García-Sanz
R, Fenton JA, Langerak AW, González M, et
al. Immunoglobulin gene rearrangements
and the pathogenesis of multiple myeloma.
Blood. 2007;110(9):3112-21. 
17. Bakkus MH, Van Riet I, Van Camp B,
Thielemans K. Evidence that the clono-
genic cell in multiple myeloma originates
from a pre-switched but somatically mutat-
ed B cell. Br J Haematol. 1994;87(1):68-74.
18. Ladetto M, Pagliano G, Ferrero S, Cavallo F,
Drandi D, Santo L, et al. Major tumor
shrinking and persistent molecular remis-
sions after consolidation with bortezomib,
thalidomide, and dexamethasone in
patients with autografted myeloma. J Clin
Oncol. 2010;28(12):2077-84. 
19. Voena C, Ladetto M, Astolfi M, Provan D,
Gribben JG, Boccadoro M, et al. A novel
nested-PCR strategy for the detection of
rearranged immunoglobulin heavy-chain
genes in B cell tumors. Leukemia. 1997;
11(10):1793-8.
20. Yousfi Monod M, Giudicelli V, Chaume D,
Lefranc MP. IMGT/JunctionAnalysis: the
first tool for the analysis of the
immunoglobulin and T cell receptor com-
plex V-J and V-D-J JUNCTIONs.
Bioinformatics. 2004;20(Suppl 1):i379-85.
21. Suzuki I, Pfister L, Glas A, Nottenburg C,
Milner EC. Representation of rearranged
VH gene segments in the human adult anti-
body repertoire. J Immunol. 1995;154(8):
3902-11. 
22. Demaison C, David D, Letourneur F, Thèze
J, Saragosti S, Zouali M. Analysis of human
VH gene repertoire expression in peripheral
CD19+ B cells. Immunogenetics. 1995;
42(5):342-52.
23. Brezinschek HP, Foster SJ, Brezinschek RI,
Dörner T, Domiati-Saad R, Lipsky PE.
Differential effects of selection and somatic
hypermutation on human peripheral
CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J
Clin Invest. 1997;99(10):2488-501.
24. Kraj P, Rao SP, Glas AM, Hardy RR, Milner
EC, Silberstein LE. The human heavy chain
Ig V region gene repertoire is biased at all
stages of B cell ontogeny, including early pre-
B cells. J Immunol. 1997;158(12):5824-32.
25. Raaphorst FM, Raman CS, Tami J,
Fischbach M, Sanz I. Human Ig heavy chain
CDR3 regions in adult bone marrow pre-B
cells display an adult phenotype of diversi-
ty: evidence for structural selection of DH
amino acid sequences. Int Immunol. 1997;
9(10):1503-15.
26. Wang X, Stollar BD. Immunoglobulin VH
gene expression in human aging. Clin
Immunol 1999;93:132-42. 
27. Larkin MA, Blackshields G, Brown NP,
Chenna R, McGettigan PA, McWilliam H,
et al. Clustal W and Clustal X version 2.0.
Bioinformatics. 2007;23(21):2947-8. 
28. Messmer BT, Albesiano E, Efremov DG,
Ghiotto F, Allen SL, Kolitz J, et al. Multiple
distinct sets of stereotyped antigen recep-
tors indicate a role for antigen in promoting
chronic lymphocytic leukemia. J Exp Med.
2004;200(4):519-25. 
29. Darzentas N, Hadzidimitriou A, Murray F,
Hatzi K, Josefsson P, Laoutaris N, et al. A dif-
ferent ontogenesis for chronic lymphocytic
leukemia cases carrying stereotyped antigen
receptors: molecular and computational evi-
dence. Leukemia. 2010;24(1):125-32. 
30. Wu YC, Kipling D, Leong HS, Martin V,
Ademokun AA, Dunn-Walters DK. High-
throughput immunoglobulin repertoire
analysis distinguishes between human IgM
memory and switched memory B-cell pop-
ulations. Blood. 2010;116(7):1070-8.
31. Ghia P, Stamatopoulos K, Belessi C,
Moreno C, Stella S, Guida G, et al.
Geographic patterns and pathogenetic
implications of IGHV gene usage in chronic
lymphocytic leukemia: the lesson of the
IGHV3-21 gene. Blood. 2005;105(4):1678-
85.
